Neurol. praxi. 2021;22(2):128-131 | DOI: 10.36290/neu.2021.003

Early diagnosis and treatment of multiple sclerosis

MUDr. Marek Peterka1, 2, MUDr. Pavel Potužník1
1 Neurologická klinika LF UK a FN Plzeň
2 Neurologická klinika LF a FN Hradec Králové

Multiple sclerosis is a chronic autoimmune disease of the central nervous system requiring early diagnosis and treatment. Currently, there is no specific test to confirm the diagnosis of multiple sclerosis. Therefore, the diagnostic process continues to be based on three main principles: clinical analysis compatible with the diagnosis (type of symptoms, their progression in time, the person's age and sex, etc.), evidence of process dissemination in time and space, and exclusion of alternative diagnoses. Given the importance of early diagnosis, the diagnostic criteria were revised in 2017, again highlighting the importance of detecting intrathecal oligoclonal band synthesis. Newly, the presence of oligoclonal bands can replace dissemination in time in establishing the diagnosis. These changes should facilitate establishing early diagnosis that can be followed by immediate treatment.

Keywords: multiple sclerosis, disability, initial clinical attack, diagnostic criteria, early treatment.

Received: December 22, 2020; Revised: December 22, 2020; Accepted: January 4, 2021; Prepublished online: January 4, 2021; Published: April 30, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Peterka M, Potužník P. Early diagnosis and treatment of multiple sclerosis. Neurol. praxi. 2021;22(2):128-131. doi: 10.36290/neu.2021.003.
Download citation

References

  1. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‑blind, placebo‑controlled trial. Lancet 2009; 374: 1503-1511. Go to original source... Go to PubMed...
  2. Compston A, Coles A. Multiple sclerosis. Lancet 2002 Apr 6; 359(9313): 1221-31. doi: 10.1016/S0140-6736(02)08220-X. Erratum in: Lancet 2002; 360(9333): 648. Go to original source... Go to PubMed...
  3. Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, Bischof A, Gundel T, Zhu AH, Papinutto N, Stern WA, Bevan C, Romeo A, Goodin DS, Gelfand JM, Graves J, Green AJ, Wilson MR, Zamvil SS, Zhao C, Gomez R, Ragan NR, Rush GQ, Barba P, Santaniello A, Baranzini SE, Oksenberg JR, Henry RG, Hauser SL. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 2019; 85(5): 653-666. Go to original source... Go to PubMed...
  4. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7(3): 268-77. doi: 10.1016/S1474-4422(08)70042-5. PMID: 18275928. Go to original source... Go to PubMed...
  5. Feinstein A, DeLuca J, Baune BT, Filippi M, Lassman H. Cognitive and neuropsychiatric disease manifestations in MS. Mult Scler Relat Disord 2013; 2(1): 4-12. Go to original source... Go to PubMed...
  6. Hauser S, et al. Harrison's Neurology in Clinical Medicine (Fourth Edition), McGraw-Hill Education, 2017.
  7. Havrdová E, a kol. Roztroušená skleróza. Praha: Mladá fronta, 2013.
  8. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. Intramuscular interferon beta 1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904. Go to original source... Go to PubMed...
  9. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group. Long‑term effect of early treatment with interferon beta‑1β after a first clinical event suggestive of multiple sclerosis: 5‑year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987-997. Go to original source... Go to PubMed...
  10. Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O'Connor PW, Simon JH; Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance Investigators. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012; 69(2): 183-190. Go to original source... Go to PubMed...
  11. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006; 77(8): 918-926. Go to original source... Go to PubMed...
  12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-1452. Go to original source... Go to PubMed...
  13. Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133:1900-13. Go to original source... Go to PubMed...
  14. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; TOPIC Study Group. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 977-86. Go to original source... Go to PubMed...
  15. Oksenberg JR, Baranzini SE, Hauser SL. Biological concepts of multiple sclerosis pathogenesis and relationship to treatment. In: Cohen JA, Rudick RA, (eds), Multiple Sclerosis Therapeutics, 3rd edition. London: Informa Healthcare, 2007: 23-44. Go to original source...
  16. Pfleger CC, Flachs EM, Koch-Henriksen N. Social consequences of multiple sclerosis: early pension and temporary unemployment - a historical prospective cohort study. Mult Scler. 2010; 16(1): 121-126. Go to original source... Go to PubMed...
  17. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162-173. Go to original source... Go to PubMed...
  18. Torkildsen GN, Lie SA, Aarseth JH, Nyland H, Myhr KM. Survival and cause of death in multiple sclerosis: results from a 50year follow-up in Western Norway. Mult Scler 2008; 14(9): 1191-1198. Go to original source... Go to PubMed...
  19. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transaction in the lesion of multiple sclerosis. N Engl J Med 1998; 338: 278-285. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.